Cumberland pharmaceuticals reports third quarter 2024 financial results and company update

–        new real world study of 150,000 patients favors caldolor over ketorolac   – –        dmd program receives fda orphan drug & rare pediatric disease designations   – nashville, tenn. , nov. 7, 2024 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company, today announced that its portfolio of fda-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024.
CPIX Ratings Summary
CPIX Quant Ranking